News | March 21, 2024
Bristol Myers Squibb completes acquisition of Karuna Therapeutics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Additional capacity broadens Grace’s fine chemical capabilities for API production
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
BHL will undertake the development and supply of these molecules
The facility will accommodate over 1,500 employees
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
We are achieving the target of developed India by making our young children healthy today
Subscribe To Our Newsletter & Stay Updated
